Provider of fertility and family-building benefits, connecting employees at partner employers with a curated fertility clinic network.
Provider of fertility and family-building benefits, connecting employees at partner employers with a curated fertility clinic network.
Employers pay it for a fertility benefit, and it pays the clinics in its network, keeping the difference; revenue grows as more employers enrol and more members use the benefit, so client wins and utilization drive results. Its negotiated bundles at fixed prices aim to control costs for the employer.
Moat: narrow (network effects, data, switching costs). Curated high-quality clinic network and outcomes data differentiate from broader insurance-based fertility coverage.
Headquarters: New York, New York · Founded: 2015 · Employees: 856
Size Progyny (PGNY) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $2.66B, the 1611th largest of 3,085 United States companies the cockpit tracks. Shares closed at $36.16 on 18 Nov 2026.
Performance Over six months the shares gained 41.0%, against +49.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 6 in its peer set.
Growth Revenue grew 5.5% over the last twelve months (peer median +11.3%); the operating margin is 9.4% (peer median 1.7%).
Valuation It trades at 23.2× forward earnings against a peer median of 26.6× (2nd cheapest of 4).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 31.0 points above its cost of capital (9.9% WACC).
Short interest Short interest is 6.5% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.34B | $1.29B | $1.17B | $1.09B | $787M |
| Revenue growth | — | +10% | +7% | +38% | — |
| Gross profit | $333M | $304M | $253M | $239M | $167M |
| EBITDA | $132M | $90.2M | $70.6M | $64.5M | $24.9M |
| Net income | $91.0M | $58.5M | $54.3M | $62.0M | $30.4M |
| Free cash flow | $180M | $192M | $174M | $185M | $77.2M |
| Capital expenditure | $27.5M | $18.4M | $5.41M | $3.64M | $3.24M |
| Total debt | $25.9M | $27.7M | $19.3M | $19.4M | $7.71M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGNY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.5% | +1.1% | highest of 6 |
| 6-month return | +41.0% | +49.6% | 3rd lowest of 6 |
| Distance from 52-week high | -2.8% | -6.8% | 3rd highest of 6 |
| Revenue growth (TTM) | +5.5% | +11.3% | 3rd lowest of 6 |
| Operating margin | 9.4% | 1.7% | 2nd highest of 6 |
| Forward P/E | 23.2× | 26.6× | 2nd cheapest of 4 |
| Growth the price implies (Req g, 7 yrs) | 8.6% | 26.3% | least demanding of 5 |
| Growth delivered (Del g) | +30.2% | +3.1% | 2nd highest of 5 |
| Hurdle (Req g minus delivered) | -21.6 pp | +18.3 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +31.0 pp | -4.9 pp | highest of 5 |
| EV / EBITDA | 18.8× | n/a | — |
| Net debt / EBITDA | -1.3× | -0.7× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Progyny PGNY | United States | $2.66B | +41% | +6% | 9% | 23.2× | 8.6% | +30.2% |
| Fortrea FTRE | United States | $1.98B | +50% | -3% | 2% | 21.6× | 31.9% | +1.1% |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +244% | -98% | -11,920% | n/a | n/a | n/a |
| Eisai 4523.T | Japan | $9.36B | +11% | +11% | 6% | 26.6× | 10.7% | +5.0% |
| OmniAb OABI | United States | $741M | +97% | +91% | -116% | n/a | 60.6% | -31.9% |
| WuXi XDC Cayman 2268.HK | Hong Kong | $10.4B | +20% | +42% | 28% | 35.8× | 20.6% | +126.4% |